Clinical trial
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents…
NCT00092495 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092495 |
|---|---|
| Title | Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) |
| Official title | A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Genital Warts |
| Intervention type | Biological |
| Interventions | V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine |
| Enrollment | 3,055 |
| Start date | Dec 1, 2002 |
| Primary completion | Sep 1, 2004 |
| Completion | Feb 1, 2009 |
| First posted | Sep 27, 2004 |
| Last update posted | Jan 13, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: